Cargando…
Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease
Patients with progressive chronic kidney disease (CKD) commonly develop mineral and bone abnormalities and extraskeletal calcifications with following increased cardiovascular risk. A key pathophysiological role is played by hyperphosphatemia. Since diet and dialysis are often insufficient to contro...
Autores principales: | Cernaro, Valeria, Calimeri, Sebastiano, Laudani, Alfredo, Santoro, Domenico |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501956/ https://www.ncbi.nlm.nih.gov/pubmed/32982259 http://dx.doi.org/10.2147/TCRM.S196805 |
Ejemplares similares
-
Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate
por: Persy, Veerle P, et al.
Publicado: (2009) -
Effect of low-dose lanthanum carbonate on calcium and phosphorus metabolism in Asian Patients with end-stage renal disease, maintenance hemodialysis and hyperphosphatemia
por: Cui, Xiaofei, et al.
Publicado: (2022) -
The management of hyperphosphatemia by lanthanum carbonate in chronic kidney disease patients
por: Shigematsu, Takashi, et al.
Publicado: (2012) -
Efficacy of crushed lanthanum carbonate for hyperphosphatemia in hemodialysis patients undergoing tube feeding
por: Kitajima, Yukie, et al.
Publicado: (2011) -
Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation – safety, efficacy, and patient adherence
por: Lloret, MªJesús, et al.
Publicado: (2013)